CJC-1295 vs Ipamorelin
CJC-1295 and Ipamorelin are growth-hormone-secretagogue research peptides that act on two different receptor systems, which is why they are so often compared and studied as a pair.
CJC-1295 (No DAC)
GHRH analogue fragment — studied for growth hormone secretagogue effects.
Ipamorelin
Synthetic pentapeptide ghrelin receptor agonist supplied for in-vitro receptor-binding and signalling research.
| CJC-1295 (No DAC) | Ipamorelin | |
|---|---|---|
| Class | GHRH analogue | Ghrelin-mimetic / GHRP |
| Receptor studied | GHRH receptor | GH-secretagogue receptor (ghrelin receptor) |
| Research context | Growth-hormone-releasing pathway models | Selective GH-pulse and receptor-selectivity models |
| Selectivity note | Acts upstream on the GHRH axis | Studied for minimal effect on cortisol/prolactin pathways |
| Common pairing | Frequently modelled alongside a GHRP | Frequently modelled alongside a GHRH analogue |
Studied together?
These two are often examined as a pair. HelixCore stocks a single combined research vial.
View the combined blend →Common questions
Why are CJC-1295 and Ipamorelin compared?
They act on two different receptor systems in the growth-hormone axis — CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin/GH-secretagogue receptor. Research often examines them together because the two pathways are studied as complementary.
What is the CJC-1295 + Ipamorelin blend?
It is a single research vial combining both peptides, used in protocols that study the two receptor pathways together rather than reconstituting two separate vials.
For research use only. Products are supplied for in-vitro laboratory research and are not for human or veterinary use. Comparison describes research context and mechanism only; it is not guidance for use.